Model for inhibition of HCV NS5b polymerase by nucleoside analogs

被引：0
|
作者：
Perry, Jason K. [1 ]
机构：
[1] Gilead Sci Inc, Struct Chem, Foster City, CA 94404 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2011年 / 242卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
202-COMP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
    Hebner, Christy M.
    Han, Bin
    Brendza, Katherine M.
    Nash, Michelle
    Sulfab, Maisoun
    Tian, Yang
    Hung, Magdeleine
    Fung, Wanchi
    Vivian, Randall W.
    Trenkle, James
    Taylor, James
    Bjornson, Kyla
    Bondy, Steven
    Liu, Xiaohong
    Link, John
    Neyts, Johan
    Sakowicz, Roman
    Zhong, Weidong
    Tang, Hengli
    Schmitz, Uli
    PLOS ONE, 2012, 7 (06):
  • [32] Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold
    Zhong, Min
    Peng, Eric
    Huang, Ningwu
    Huang, Qi
    Huq, Anja
    Lau, Meiyen
    Colonno, Richard
    Li, Leping
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (05) : 963 - 968
  • [33] Neohexyl derivatives of B-ring alkylaminobenzothiadiazine inhibitors of HCV NS5B polymerase
    Randolph, John T.
    Huang, Peggy P.
    Hutchinson, Douglas K.
    Klein, Larry L.
    Montgomery, Debra A.
    Masse, Sherie V.
    Kati, Warren M.
    Beno, David
    Kempf, Dale J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 730 - 730
  • [34] HCV NS5A inhibition impacts immune exhaustion more than NS5B or NS3 inhibition
    Miller, K.
    Slauenwhite, D.
    Arseneault, K.
    Oldford, S.
    Barrett, L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S539 - S539
  • [35] NS5B polymerase inhibitors in phase II clinical trials for HCV infection
    Borgia, Guglielmo
    Maraolo, Alberto Enrico
    Nappa, Salvatore
    Gentile, Ivan
    Buonomo, Antonio Riccardo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) : 243 - 250
  • [36] IMPACT OF ANTIRETROVIRAL THERAPY ON THE VARIABILITY OF THE HCV NS5B POLYMERASE IN HIV/HCV COINFECTED PATIENTS
    Plaza, Z.
    Soriano, V.
    Bar-Magen, T.
    Gonzalez, M. M.
    Di Lello, F.
    Macias, J.
    Labarga, P.
    Pineda, J. A.
    Poveda, E.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S486 - S486
  • [37] Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase
    Cheng, Cliff C.
    Huang, Xiaohua
    Shipps, Gerald W., Jr.
    Wang, Yu-Sen
    Wyss, Daniel F.
    Soucy, Kyle A.
    Jiang, Chuan-kui
    Agrawal, Sony
    Ferrari, Eric
    He, Zhiqing
    Huang, H-C
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 466 - 471
  • [38] Cyclic phosphate prodrugs of 2′-deoxy-2¢-fluoro-2¢-C-methyl nucleoside analogs as inhibitors of HCV NS5B polymerase
    Reddy, P. Ganapati
    Bao, Donghui
    Chang, Wonsuk
    Chun, Byoung-Kwon
    Du, Jinfa
    Nagarathnam, Dhanapalan
    Rachakonda, Suguna
    Ross, Bruce S.
    Zhang, Hai-Ren
    Bansal, Shalini
    Espiritu, Christine L.
    Keilman, Meg
    Lam, Angela M.
    Niu, Congrong
    Steuer, Holly M.
    Furman, Phillip A.
    Otto, Michael J.
    Sofia, Michael J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [39] Diastereoselective synthesis of a purine phosphoramidate prodrug inhibitor of HCV NS5B polymerase
    Zhang, Hai-Ren
    Reddy, P. Ganapati
    Ross, Bruce S.
    Rachakonda, Suguna
    Sofia, Michael J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [40] Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors
    Wang, M.
    Zhong, M.
    Yan, A.
    Li, L.
    Yu, C.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2014, 25 (01) : 1 - 15
12345